Aspira Women's Health (AWH) said late Tuesday that the New York State Department of Health's Clinical Laboratory Evaluation Program has approved OvaWatch, its non-invasive blood test for ovarian cancer risk assessment.
The company said the approval allows OvaWatch to be marketed in New York state.
Shares of the company were up 2% in after-hours activity.
Price: 0.8000, Change: +0.02, Percent Change: +2.04
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.